Sign in to view content

Agitation of the Syringe as a Cause of Inflammation After Intravitreal Injection of Aflibercept: A Randomized, Double-blind, Controlled Clinical Trial

Gustavo Barreto de Melo, MD, PhD, FASRS

Video
Published 2020

Related

Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more